Atara Biotherapeutics, INC 10-Q quarterly reports

Atara Biotherapeutics achieved a net income of $36.1 million for the first nine months of 2025, driven by significant cost reductions and strategic realignments, despite ongoing liquidity concerns.

Atara Biotherapeutics reported a net income for the first half of 2025, driven by strategic asset transfers and significant workforce reductions, while facing ongoing liquidity challenges.

Atara Biotherapeutics reports a net income of $38.0 million for Q1 2025, driven by commercialization revenue, and completes the transfer of manufacturing responsibilities to Pierre Fabre.

Atara Biotherapeutics reports third quarter 2024 results, highlighting commercialization revenue growth and progress in its clinical programs, including the acceptance of the tab-cel BLA by the FDA.

Atara Biotherapeutics' second quarter 2024 report highlights commercialization revenue growth and progress in clinical development, while also noting ongoing financial challenges.

Atara Biotherapeutics reports a net loss of $31.8 million for the first quarter of 2024, while progressing its T-cell immunotherapy programs and manufacturing capabilities.